CCR5抑制剂作为HIV-1感染治疗药物的研发现状与挑战。

The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.

作者信息

Maeda Kenji, Nakata Hirotomo, Ogata Hiromi, Koh Yasuhiro, Miyakawa Toshikazu, Mitsuya Hiroaki

机构信息

Department of Infectious Diseases, Kumamoto University School of Medicine, Kumamoto 860-8556, Japan.

出版信息

Curr Opin Pharmacol. 2004 Oct;4(5):447-52. doi: 10.1016/j.coph.2004.07.004.

DOI:10.1016/j.coph.2004.07.004

PMID:15351348

Abstract

The discovery of CCR5 as a HIV-1 co-receptor unfolded the cryptic and complicated process of HIV-1 cellular entry and has provided more than a few entry steps as possible modalities for effective viral intervention. The proof-of-principle has already been established for the use of entry inhibitors against HIV-1 and there is a cautious optimism that several CCR5 inhibitors might soon be added to our armamentarium for therapy of HIV-1 infection.

摘要

CCR5作为HIV-1共受体的发现揭示了HIV-1进入细胞这一隐秘而复杂的过程，并提供了多个进入步骤，作为有效的病毒干预的可能方式。针对HIV-1使用进入抑制剂的原理验证已经确立，人们谨慎乐观地认为，几种CCR5抑制剂可能很快会被添加到我们治疗HIV-1感染的武器库中。